Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKOVAZ vs BACIGUENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
Treatment of clinically important hypotension occurring in the setting of anesthesia
Topical treatment of superficial skin infections caused by susceptible strains of Staphylococcus spp., Streptococcus spp., and other gram-positive bacteria,Prophylaxis of minor skin infections,Off-label: Prevention of infection in minor cuts, scrapes, and burns
5 mg intravenously once daily.
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria)
Hepatic metabolism via oxidative deamination and demethylation; primarily metabolized by CYP2D6; some metabolites are active.
Bacitracin undergoes minimal systemic absorption via topical application; not significantly metabolized; excreted unchanged in urine if absorbed.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%)
85% bound to albumin and alpha-1-acid glycoprotein.
Approximately 20–30% bound to serum proteins, mainly albumin
Vd: 1.5-2.0 L/kg, indicating extensive tissue distribution.
0.25–0.4 L/kg (total body water); limited tissue distribution, primarily extracellular fluid
Oral: 75% (first-pass metabolism minimal).
Topical: negligible systemic absorption (<0.5%) through intact skin; oral: not absorbed (inactivated in GI tract; not used systemically)
Not required as AKOVAZ is not renally excreted.
No dose adjustment required for topical use; systemic absorption is minimal.
No dose adjustment needed based on Child-Pugh classification.
No dose adjustment required for topical use.
0.1 mg/kg intravenously once daily, maximum 5 mg.
Apply thin layer to affected area 1 to 3 times daily; safety in infants under 2 months not established.
No specific dose adjustment required; use caution due to potential age-related decreased renal function.
No specific dose adjustment; use same as adult dosing.
None
Due to nephrotoxicity, bacitracin is NOT recommended for parenteral use; topical use only.
Hypertension: May cause severe hypertension, including hypertensive crisis, especially with concurrent MAOIs or other vasopressors.,Arrhythmias: May induce ventricular arrhythmias, especially in patients with underlying cardiac disease.,Risk of stroke: Hypertensive effects may increase risk of intracranial hemorrhage.,Tachyphylaxis: Repeated use may lead to decreased response.,Extravasation: Risk of tissue necrosis if extravasation occurs.,Use caution in patients with hyperthyroidism, pheochromocytoma, or diabetes.
Hypersensitivity reactions including anaphylaxis,Prolonged use may result in overgrowth of non-susceptible organisms, including fungi,Avoid contact with eyes,Not for use on deep wounds or severe burns
Hypersensitivity to ephedrine or other sympathomimetics,Concurrent use with MAOIs or within 14 days after discontinuation,Angle-closure glaucoma,Severe hypertension or cardiovascular disease
Hypersensitivity to bacitracin or any component of the formulation
No known food interactions. This drug is administered intravenously, so dietary restrictions are not applicable. However, oral intake should not interfere with therapy.
No known food interactions with topical bacitracin. Avoid ingestion.
Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. In second and third trimesters, use may cause fetal tachycardia, reduced uteroplacental blood flow, and potential for neonatal withdrawal or toxicity. Risk of maternal hypertension and decreased uterine perfusion outweighs benefits unless clearly indicated.
Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contraindicated due to nephrotoxicity, and limited data exist for systemic use in pregnancy. Animal studies show no evidence of harm, but human data are insufficient.
Ephedrine is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 2.5-3.0. Peak milk concentration occurs 1-2 hours after dose. Potential for infant stimulation, irritability, and sleep disturbances. Use with caution; monitor infant for adverse effects. Avoid in lactation if possible or use lowest effective dose for shortest duration.
Bacitracin is not systemically absorbed from topical use; therefore, breast milk exposure is negligible. M/P ratio is not applicable. Considered safe during breastfeeding when used topically. For systemic use, avoid due to potential nephrotoxicity.
Pharmacokinetic changes in pregnancy (increased plasma volume, altered binding proteins) may reduce peak concentrations of ephedrine. However, no specific dose adjustment recommendations are established for Akovaz in pregnancy. Use the lowest effective dose to achieve desired effect (typically 5-10 mg IV for hypotension). Monitor clinical response closely; dose titration may be needed due to altered sensitivity of adrenergic receptors in pregnancy. Avoid prolonged use.
No dosing adjustment needed for topical bacitracin. Systemic use is contraindicated in pregnancy due to risk of maternal nephrotoxicity; if unavoidable, use with extreme caution and monitor renal function, but no specific dose recommendations exist.
AKOVAZ (ceftolozane/tazobactam) is a cephalosporin/beta-lactamase inhibitor combination used primarily for hospital-acquired pneumonia and complicated urinary tract infections. Monitor renal function closely; dose adjustment required for Cr Cl < 50 m L/min. Administer intravenously over 1 hour. Observe for hypersensitivity reactions, including anaphylaxis, particularly in penicillin-allergic patients. Consider cross-reactivity with other beta-lactams. Collect cultures before initiation.
Bacitracin is a topical polypeptide antibiotic effective against gram-positive organisms. It is often combined with neomycin and polymyxin B in triple antibiotic ointments. For minor wounds, apply a thin layer 1-3 times daily. Avoid use on large body surface areas or for deep puncture wounds due to risk of systemic absorption and nephrotoxicity. Monitor for allergic contact dermatitis, especially with prolonged use.
This medication is given intravenously to treat serious bacterial infections.,Report any signs of allergic reaction immediately: rash, itching, difficulty breathing, swelling of face or throat.,Diarrhea may occur; contact your provider if it is severe, watery, or bloody.,Do not skip doses; complete the full course of treatment even if you feel better.,Tell your healthcare provider about all medications, especially blood thinners (e.g., warfarin) and other antibiotics.,Kidney function will be monitored with blood tests; drink adequate fluids unless told otherwise.
Clean the affected area before each application.,Apply a thin layer of ointment 1 to 3 times daily.,Do not use on large areas of the body, deep wounds, or animal bites.,Stop use and consult a doctor if the condition worsens or does not improve within 1 week.,Avoid contact with eyes or mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKOVAZ vs BACIGUENT, answered by our medical review team.
AKOVAZ is a Topical Antibiotic that works by Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.. BACIGUENT is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKOVAZ and BACIGUENT depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKOVAZ is: 5 mg intravenously once daily.. The standard adult dose of BACIGUENT is: Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKOVAZ and BACIGUENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKOVAZ is classified as Category C. Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. I. BACIGUENT is classified as Category C. Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contrai. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.